Landon Inge, PhD
Research Awards Nationwide Recipient (2013-2015)
St. Joseph's Hospital & Medical Center, Phoenix, AZ
Compound Could Help Some Patients With Non-Small Cell Lung Cancer
Non-small cell lung cancer (NSCLC) is a deadly disease, accounting for the majority of cancer-related deaths in the United States. Recent evidence points towards inactivation of the protein, LKB1, as playing a critical role in the progression of a large portion of NSCLC tumors. Work in Dr. Inge's laboratory suggests that the compound 2-Ddeoxyglucose (2DG) may cause death to NSCLC tumors deficient for LKB1. Using a genetic mouse model of LKB1 deficient NSCLC, Dr. Inge and his team will attempt to validate 2DG as a therapeutic alternative and explain the molecular mechanisms behind the anti-tumor activity of 2DG in LKB1 deficient NSCLC. This is significant, as patients lacking LKB1 face a poor prognosis. The findings will provide a new avenue for treatment of NSCLC.
Sign up for the latest lung health news delivered right to your inbox.
Join more than 500,000 people who receive research updates, inspiring stories, health information and more.